梯瓦制药 2024年度报告

AnnualReport UNITEDSTATESSECURITIESAND EXCHANGECOMMISSIONWashington,D.C.20549FORM10-K (MarkOne)~ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934Forthefiscalyearended December 31,20240TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934Forthetra nsition period fromtoCommissionfilenumber001-16174 TEVA PHARMACEUTICALINDUSTRIESLIMITED(Exactnameofregistrantas specified in itscharter) NewYor kStockExchange Securities registeredpursuanttoSection12(g)oftheAct:None Indicatebycheck mark if the registrant is a well-known seasonedissuer,asdefined in Rule405oftheSecuritiesAct.Yes~No0Indicate by checkmarkif the registrant is notrequiredtofilereports pursuant toSection13orSection15(d)ofthe Act.Yes0No~Indicatebycheckmarkwhether the registrant ( I) hasfiled all reports required to be fi ledbySection13or15(d)oftheSecuritiesExchangeActof1934 during the preceding12 months(orforsuch sho1ter period that the registrant was required to file such reports), and(2)has beensubjecttosuch filingrequirementsforthepast90days.Yes~No0Indicatebycheckmarkwhether the registrant has submitted electronicallyeveryInteractliveDataFile requiredtobesubmitted pllfsuanttoRule405of RegulationS-T(§232-405ofthis chapter) during thepreceding 12 months (or forsuchsnorterperiod that the registrantwas requi redtosubmit suchfiles.)Yes~No0 Indicatebycheckmarkwhether the registrant is a largeacceleratedfiler,anaccelerated filer, a non-accelerated filer, smaller reporting company,oranemerging growth company.Seethe definitionsof"largeacceleratedfiler,""acceleratedfiler,""smallerreportingcompany"and"emerginggrowthcompany"inRu le 12b-2oftheExchangeAct.0 Accelerated filerSmallerreponingcompany0Emerging growthcompany0Ifan emerging growthcompany, indicate by check markifthe registranthas elected not to use the extendedtransitionperiod forcomplying with any new or Large accelerated filer~Non-accelerated filer0 revised fi nanc ial accounting standards provided pursuant toSection13(a)oftheExchangeAct.0Indicatebycheckmarkwhether the registrant has filed a report on and attestation to its management'sassessmentofthe effectivenessofitsinternal control overfinancial reporting underSection404(b)oftheSarbanes-OxleyAct (15U.S.C.7262(b)) by theregistered public accounting firm that prepared o r iss ueditsaudit report.~Ifsecuritiesare registered pursuanttoSection12(b)ofthe Act,indkateby check markwhether the financial statementsofthe registrant includedinthe filing reflect the correctionofan errortopreviously issued financialstatements.~Indicate by checkmarkwhetheranyofthose error correctionsarerestatements thatrequireda recovery analys isofincentive-based compensation receivedby anyofthe registrant'sexecutive officersduring the relevant recovery period pursuant to§240.1OD-1(b).~Indicate by checkmark whether the registrantis ashellcompany (as definedinRule 12b-2ofthe Exchange Act}.Yes0No Theaggregatemarketvalueofthevoting<.:umrnunequityheldbynun-affiliatesoftheregistrant,wrnputedbyrt:ferenc.;etothedosingpric.;eatwhi<.:htheAmerican DepositaryShareswere last sold o n the NewYorkStockExchange,asofthe last busi nessdayofthe registrant's mostrecently completedsecondfiscal quarter(June30,2024},was approximately $ 18.32 billion. Teva Pharmaceutical IndustriesLimited has no non-voti ngcommonequity.Forpuri)Joseofthis calculation only, this amount excludesordi narysharesandAmerican DepositarySharesheld by directors andexecutive officersandbyeach personwhoownsormaybedeemed to own10%ormoreofthe registra nt'scommon equity atJune30,2024.AsofDecember31,2024,the registrant hadI,133,838,689 ordinary shares outstanding. Portionsofthe registrant'sdefi nitiveproxy statement for its annual meetingofshareholders to be fi led withi n120daysafterthecloseofthe registrant'sfiscal year are incorporated by reference into PartlllofthisAnnualReport on FormI0-K. TABLEOFCONTENTS Introduction andUseofCertainTerms......................................................Forward-Looking Statements PARTI ItemE.Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2Item ] A.Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29ItemIB.UnresolvedStaffComments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54ItemEC.Cybersecurity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54Item 2.Prope1ties. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56Item3.Legal Proceedings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56Item4.MineSafetyDisclosures. . . . . . . . . . . . . . . .